EU approves Tarceva for NSCLC

Europe approved Tarceva erlotinib to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Roche (SWX:ROCZ) has rights to th...